Helius Medical Technologies, Inc. (HSDT)

Market Cap	7.00M
Revenue (ttm)	787,000
Net Income (ttm)	-14.07M
Shares Out	28.21M
EPS (ttm)	-1.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,282
Open	0.240
Previous Close	0.250
Day's Range	0.240 - 0.260
52-Week Range	0.200 - 3.865
Beta	1.24
Analysts	Buy
Price Target	2.72 (+996.77%)
Earnings Date	May 11, 2023

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The compan...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Philippe Deschamps
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: HSDT

Financial Performance

In 2022, HSDT's revenue was $787,000, an increase of 50.77% compared to the previous year's $522,000. Losses were -$14.07 million, -22.39% less than in 2021.

Analyst Forecast

According to 9 analysts, the average rating for HSDT stock is "Buy." The 12-month stock price forecast is $2.72, which is an increase of 996.77% from the latest price.

Price Target

$2.72

(996.77% upside)

Analyst Consensus: Buy